Checkpoint Therapeutics, Inc.

Equities

CKPT

US1628282063

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.43 ^USD	+0.70%		-2.05%	-37.55%

Mar. 22	Checkpoint Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 18	Checkpoint Therapeutics, Inc. Appoints Amit Sharma to Its Board as an Independent, Non-Executive Director	CI

Checkpoint Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 22, 2024 at 08:30 am EDT

Checkpoint Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 0.103 million compared to USD 0.192 million a year ago. Net loss was USD 51.85 million compared to USD 62.62 million a year ago.

Basic loss per share from continuing operations was USD 3.17 compared to USD 7.09 a year ago.

Latest news about Checkpoint Therapeutics, Inc.

Checkpoint Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
Checkpoint Therapeutics, Inc. Appoints Amit Sharma to Its Board as an Independent, Non-Executive Director	Mar. 18	CI
Checkpoint Therapeutics Launches $14 Million Registered Direct Offering	Jan. 29	MT
B. Riley Lowers Checkpoint Therapeutics' Price Target to $4 From $8, Keeps Buy Rating	Dec. 20	MT
Checkpoint Therapeutics Shares Halved After FDA Complete Response Letter	Dec. 18	DJ
U.S. Food and Drug Administration Issues Complete Response Letter for Checkpoint Therapeutics, Inc.'s Cosibelimab Solely Due to Inspection Findings At Third-Party Manufacturer	Dec. 18	CI
US FDA declines to approve Checkpoint Therapeutics' skin cancer therapy	Dec. 18	RE
Checkpoint Therapeutics Gets FDA Response Letter on Cosibelimab Application	Dec. 18	DJ
North American Morning Briefing : Stocks Futures Steady on Rates Optimism	Nov. 20	DJ
Checkpoint Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer	23-10-18	CI
Checkpoint Therapeutics, Inc.(NasdaqCM:CKPT) dropped from S&P Global BMI Index	23-09-18	CI
B. Riley Lowers Checkpoint Therapeutics' Price Target to $8 From $15, Keeps Buy Rating	23-08-22	MT
North American Morning Briefing : China Trouble Hits Sentiment	23-08-18	DJ
Lake Street Adjusts Checkpoint Therapeutics Price Target to $14 From $16, Maintains Buy Rating	23-08-15	MT
Ladenburg Thalmann Adjusts Checkpoint Therapeutics' Price Target to $47 From $65, Keeps Buy Rating	23-08-15	MT
Cantor Fitzgerald Adjusts Checkpoint Therapeutics' Price Target to $14 From $19, Keeps Overweight Rating	23-08-15	MT
Checkpoint Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
North American Morning Briefing : Stock Futures -2-	23-08-11	DJ
Checkpoint Therapeutics to Raise $10 Million in Offering of Shares, Warrants; Stock Falls	23-07-31	MT
Checkpoint Therapeutics, Inc.(NasdaqCM:CKPT) dropped from Russell Microcap Growth Index	23-06-23	CI
Checkpoint Therapeutics, Inc.(NasdaqCM:CKPT) dropped from Russell 3000E Growth Index	23-06-23	CI
Lake Street Adjusts Checkpoint Therapeutics' Price Target to $16 From $22, Keeps Buy Rating	23-05-30	MT
Ladenburg Thalmann Lowers Price Target on Checkpoint Therapeutics to $65 From $69, Maintains Buy Rating	23-05-17	MT
Cantor Fitzgerald Cuts Price Target on Checkpoint Therapeutics to $19 From $54, Maintains Overweight Rating	23-05-16	MT

Chart Checkpoint Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. The Company is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber Cancer Institute, as a potential new treatment for patients with selected recurrent or metastatic cancers, including metastatic and locally advanced cutaneous squamous cell carcinoma. The Company is also evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Its anti-GITR monoclonal antibody, CK-302, is a fully human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Checkpoint Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.43 USD

Average target price

17.25 USD

Spread / Average Target

+1,106.29%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CHECKPOINT THERAPEUTICS, INC.	-37.55%	51.03M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research